Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Recurrence 1Pancreatic Neoplasms 1Neoplasm, Residual 1Leukemia, Myeloid, Acute 1Carcinoma, Renal Cell 1Advanced Solid Tumor 1

Interventions

Gemcitabine 169130-nm albumin-bound paclitaxel 54Albumin-Bound Paclitaxel 42Oxaliplatin 32Fluorouracil 31pembrolizumab 30Capecitabine 30Leucovorin 27Irinotecan 27Radiotherapy 25Nivolumab 22Erlotinib Hydrochloride 21Taxes 19Cisplatin 18Bevacizumab 15Specimen Handling 12Magnetic Resonance Spectroscopy 12Radiosurgery 11Ipilimumab 11Cyclophosphamide 11Drug Therapy 10Carboplatin 10Paclitaxel 9Docetaxel 9Cetuximab 9Biopsy 9trametinib 8olaparib 8Sorafenib 8poly ICLC 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Pancreatic Neoplasms × CD3 Complex × Clear all
NCT00056537 2014-08-27

ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer

Active Biotech AB

Phase 1 Completed
44 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡